Docoh
Loading...

ABUS Arbutus Biopharma

News

From Benzinga Pro
Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
7 Dec 21
Biotech, Long Ideas, News, Penny Stocks, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Arbutus Biopharma Corporation (NASDAQ: ABUS) has
Arbutus Biopharma, X-Chem And Proteros Announce Arbutus Has 'identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease'; Arbutues Achieves Worldwide Exclusive License To Identified Molecules
7 Dec 21
Biotech, General
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and
20 Stocks Moving in Friday's Pre-Market Session
3 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45 per share.
'Arbutus: Still Plenty of Upside Left Following Favorable Court Decision' -TipRanks Article
2 Dec 21
News, Rumors, Media
https://blog.tipranks.com/arbutus-still-plenty-of-upside-left-following-favorable-court-decision/
27 Stocks Moving in Thursday's Pre-Market Session
2 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday.
61 Biggest Movers From Yesterday
2 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet
1 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Wednesday, the Dow traded up 0.39% to 34,617.2 while the NASDAQ climbed 0.17% to 15,564.73. The S&P also rose, gaining 0.68% to 4,597.96.
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
1 Dec 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Why Arbutus Shares Are Soaring Today
1 Dec 21
News, Small Cap, Legal
Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-de
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
1 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64.
50 Stocks Moving In Wednesday's Mid-Day Session
1 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
Why Moderna Shares Are Sliding Today
1 Dec 21
News, Penny Stocks, Small Cap, Legal, Global
Moderna Inc (NASDAQ: MRNA) is trading lower Wednesday after The Patent Trial and Appeals Board turned down the company's appeal to invalidate two of Arbutus Biopharma Corp's (NASDAQ: ABUS) patents on d
Arbutus Reports Prelim. Data On Co.'s Capsid Inhibitor AB-836 Is Generally Safe, Well Tolerated, Provides Antiviral Activity
1 Dec 21
Biotech, News, FDA, General
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
1 Dec 21
News, Penny Stocks, Health Care, Small Cap, Legal, Movers, Media, Trading Ideas, General
Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday.
Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views
1 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbed 1.40% to 15,755.57. The S&P also rose, gaining 1.39% to 4,630.57.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $9
8 Nov 21
News, Price Target, Analyst Ratings
JMP Securities analyst Jason Butler maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price target from $7 to $9.
26 Stocks Moving in Monday's Pre-Market Session
8 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus.
Arbutus Biopharma Q3 EPS $(0.24), Inline, Sales $3.34M Beat $2.38M Estimate
4 Nov 21
Earnings, News
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year.
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.

Press releases

From Benzinga Pro
Thinking about buying stock in ACADIA Pharmaceuticals, Arbutus Biopharma, Jumia Technologies, Bright Health Group, or Argo Blockchain?
7 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ABUS, JMIA, BHG, and ARBK.
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
7 Dec 21
Health Care, Press Releases
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks WARMINSTER, Pa. and
Thinking about buying stock in Phunware, Omeros Corp, Humanigen, Spirit AeroSystems, or Arbutus Biopharma?
2 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, OMER, HGEN, SPR, and ABUS.
Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
1 Dec 21
Health Care, Press Releases, General
WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad
Thinking about buying stock in Arbutus Biopharma, Beyondspring, Cumberland Pharmaceuticals, Delta Air Lines, or T2 Biosystems?
1 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, BYSI, CPIX, DAL, and TTOO.
Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
11 Nov 21
Biotech, News, Management, Press Releases, General
WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
10 Nov 21
Biotech, News, Health Care, Press Releases, General
Arbutus' Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of AB-729 Repeat dosing of both 60
Arbutus to Participate at Jefferies London Healthcare Conference
10 Nov 21
Biotech, News, Health Care, Press Releases, General
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4 Nov 21
Biotech, Earnings, Press Releases, General
On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog ("NA") therapy On-track to
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
21 Oct 21
Biotech, News, Press Releases, General
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad
Thinking about buying stock in Tata Motors, New Fortress Energy, Arbutus Biopharma, US Well Services, or Progenity?
7 Oct 21
Fintech, Press Releases
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTM, NFE, ABUS, USWS, and PROG.
Arbutus to Participate in October Investor Conferences
28 Sep 21
News, Press Releases
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
21 Sep 21
Press Releases
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for
Thinking about buying stock in IVERIC bio, T2 Biosystems, Endo International, Arbutus Biopharma, or Katapult?
10 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISEE, TTOO, ENDP, ABUS, and KPLT.